Moreover, it is known that TRPA1 agonists in the hippocampus lead to the depressive-and anxiolytic-like effects, while pharmacological blockage or TRPA1 gene deletion reduce the depression-and anxiolytic-like symptoms. This evidence concerns the gene TRPA1 and major depressive disorder.